Ignite Creation Date:
2024-05-06 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 12:41 PM
Study NCT ID:
NCT03449784
Status:
RECRUITING
Last Update Posted:
2022-07-05
First Post:
2018-02-22
Brief Title:
Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias
Sponsor:
University Hospital Montpellier
Organization:
University Hospital Montpellier
Study Overview
Official Title:
Observatory of Patients With Dyslipidemia Hospitalized in Endocrinology-Diabetology-Nutrition Unit Observational Study
Status:
RECRUITING
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OBDYSLIP
Brief Summary:
Cardiovascular disease CVD due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years in Europe and is also increasingly common in developing countries In the European Union the economic cost of CVD represents annually 192 billion in direct and indirect healthcare costs The main clinical entities are coronary artery disease CAD ischaemic stroke and peripheral arterial disease PAD The causes of these CVDs are multifactorial Some of these factors relate to lifestyles such as tobacco smoking lack of physical activity and dietary habits and are thus modifiable Other risk factors are also modifiable such as elevated blood pressure type 2 diabetes and dyslipidaemias or non-modifiable such as age and male gender LDL-cholesterol LDL-C is one of the major risk factors for CVD through its role in the development of atherosclerosis The efficacy of statins has been demonstrated by a considerable amount of literature not only in lowering LDL cholesterol levels but also in reducing cardiovascular events both in diabetes and non-diabetes patients Guidelines for the management of dyslipidemia have emerged from different countries Thereby in 2016 the French Society of Endocrinology SFE and the New French Society of Atherosclerosis NSFA published a consensus statement on the management of dyslipidemias integrating features from European recommendations and in 2017 the Haute Autorité de Santé updated the French guidelines However LDL-C goal attainment has rarely been assessed specifically in diabetes population in which CVD is of particular importance This study aimed to assess the rate of dyslipidaemias in a population of patient hospitalized in Endocrinology-Diabetology-Nutrition unit
This observational study was carried in the Diabetes-Nutrition unit of the University Hospital of Montpellier - France All consecutive patients admitted to that unit during the study period were assessed for eligibility Data on age sex tobacco smoking body mass index hypertension treatment of previously diagnosed hypertension or blood values 14090 mmHg presence and type of CVD coronary artery disease stroke and transient ischemic attack peripheral arterial disease were collected at admission LDL-C HDL-C and triglycerides levels calculated with the Friedewald formula and glomerular filtration rate calculated according to the CKD-EPI formula were obtained from blood samples taken within 24 hours of hospitalization admission Information on the name and daily dose of lipid lowering drugs statins fibrate ezetimibe at admission was documented Cardiovascular risk level and LDL-C target values were defined according to 2011 and 2016 ESC guidelines and 2017 French guidelines
This observational study was carried in the Diabetes-Nutrition unit of the University Hospital of Montpellier - France All consecutive patients admitted to that unit during the study period were assessed for eligibility Data on age sex tobacco smoking body mass index hypertension treatment of previously diagnosed hypertension or blood values 14090 mmHg presence and type of CVD coronary artery disease stroke and transient ischemic attack peripheral arterial disease were collected at admission LDL-C HDL-C and triglycerides levels calculated with the Friedewald formula and glomerular filtration rate calculated according to the CKD-EPI formula were obtained from blood samples taken within 24 hours of hospitalization admission Information on the name and daily dose of lipid lowering drugs statins fibrate ezetimibe at admission was documented Cardiovascular risk level and LDL-C target values were defined according to 2011 and 2016 ESC guidelines and 2017 French guidelines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None